Back to today’s briefing

Story perspectives

Teva Sues Biden Over Medicare Drug Price Negotiation

1/16/2025

42 5

Summary

Story summary

Teva Pharmaceuticals has taken a bold step, suing the Biden administration over the Medicare Drug Price Negotiation Program, which targets the Inflation Reduction Act. In a promising twist, a report reveals that the new $2,000 cap on out-of-pocket drug costs could bring relief to millions of Medicare patients grappling with soaring prescription prices.

1 of 1

Story summary

Teva Pharmaceuticals has taken a bold step, suing the Biden administration over the Medicare Drug Price Negotiation Program, which targets the Inflation Reduction Act. In a promising twist, a report reveals that the new $2,000 cap on out-of-pocket drug costs could bring relief to millions of Medicare patients grappling with soaring prescription prices.